Cantor Fitzgerald Forecasts Immatics FY2025 Earnings

Immatics (NASDAQ:IMTX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Immatics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($1.34) for the year. The consensus estimate for Immatics' current full-year earnings is ($0.79) per share.

A number of other equities research analysts have also recently commented on IMTX. The Goldman Sachs Group raised Immatics to a "strong-buy" rating in a research note on Monday, November 25th. Bank of America cut their price target on shares of Immatics from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, November 19th. Finally, Piper Sandler assumed coverage on shares of Immatics in a report on Monday, October 7th. They issued an "overweight" rating and a $19.00 price objective for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $16.67.

Immatics Price Performance

IMTX stock traded up $0.06 on Wednesday, reaching $5.46. 393,841 shares of the company traded hands, compared to its average volume of 949,108. The firm has a fifty day simple moving average of $7.22 and a 200-day simple moving average of $9.73. The company has a market cap of $651.71 million, a P/E ratio of -8.27 and a beta of 0.77. Immatics has a one year low of $5.27 and a one year high of $13.77.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in Immatics in the 2nd quarter worth approximately $321,000. Cubist Systematic Strategies LLC bought a new stake in shares of Immatics in the second quarter worth $2,404,000. The Manufacturers Life Insurance Company increased its position in Immatics by 13.9% during the second quarter. The Manufacturers Life Insurance Company now owns 150,769 shares of the company's stock valued at $1,752,000 after acquiring an additional 18,354 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new position in Immatics in the second quarter valued at about $13,392,000. Finally, Forefront Analytics LLC purchased a new position in Immatics in the second quarter worth about $139,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.